Global Wealth Strategies & Associates Lowers Stake in Eli Lilly and Company $LLY

Global Wealth Strategies & Associates lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 372 shares of the company’s stock after selling 31 shares during the period. Global Wealth Strategies & Associates’ holdings in Eli Lilly and Company were worth $290,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Duquesne Family Office LLC grew its holdings in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC bought a new stake in Eli Lilly and Company in the 1st quarter worth $570,000. LS Investment Advisors LLC grew its holdings in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock worth $1,933,000 after acquiring an additional 40 shares during the last quarter. Cutter Capital Management LP bought a new stake in Eli Lilly and Company in the 1st quarter worth $14,866,000. Finally, Prism Advisors Inc. bought a new stake in Eli Lilly and Company in the 1st quarter worth $207,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.2%

Shares of NYSE LLY opened at $754.90 on Friday. The firm’s 50 day moving average price is $741.03 and its 200-day moving average price is $776.40. The company has a market cap of $714.48 billion, a PE ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $942.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks acquired 1,632 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

LLY has been the topic of a number of research reports. UBS Group cut their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Cantor Fitzgerald cut their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Guggenheim lowered their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $941.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.